ABSTRACT
INTRODUCTION The morbidity and mortality related to metastatic breast cancer remains high, a fact which necessitates the optimisation of the role of imaging in breast cancer management. Functional imaging approaches are now being increasingly used in oncological management, the principal advantage relative to anatomical imaging being that sites of active disease are accurately assessed. A particularly exciting development in recent years has been that of the advent of positron emission tomography/computed tomography (PET/CT) scanners, providing functional information regarding disease status (defi ning sites of active/inactive disease) combined with the anatomical defi nition of CT.
